The GrŸnenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a Û 2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation. GrŸnenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the GrŸnenthal Group worldwide. In 2016, GrŸnenthal achieved revenues of approx. Û 1.4 bn. More information: www.grunenthal.com. Search fields for Licensing & Acquisition R&D (from late preclinical to late stage clinical development, focus on small indications, clear differentiation vs. standard of care) Perioperative care Inflammation (niches in rheumatic diseases and other inflammatory diseases) Niche indication and rare diseases Cancer Supportive Care Europe (marketed RX-products for the retail- and or / or hospital business) Pain Perioperative Care Inflammation Neurology/Psychiatry Cancer Supportive Care Bone disorders Movement disorders Latin America (marketed RX-products for the retail- and or / or hospital business) Urology Gynecology Pain Inflammation Neurology/Psychiatry Cancer Supportive Care GrŸnenthalÕs Innovative Medicines Unit: www.imu.grunenthal.com GrŸnenthalÕs innovative INTAC¨ technology: www.intac.grunenthal.com Jobs & Career: http://careers.grunenthal.com/ Imprint: http://grunenthal.com/grt-web/Grunenthal_Group/Service/Imprint/130200018.jsp